# A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct07662213` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07662213](<https://clinicaltrials.gov/study/NCT07662213>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07662213

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.

## Technical summary

Registry record NCT07662213. Randomized; no masking; primary purpose treatment. Start 2026-07-06 (actual); primary completion 2028-05-23 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1200 participants (planned count; ClinicalTrials.gov record NCT07662213, source copy `cardio:ctgov-nct07662213-2026-10-22`, retrieved 2026-10-26)
- Started: 2026-07-06 (actual) (ClinicalTrials.gov record NCT07662213, source copy `cardio:ctgov-nct07662213-2026-10-22`, retrieved 2026-10-26)
- Primary completion: 2028-05-23 (anticipated) (ClinicalTrials.gov record NCT07662213, source copy `cardio:ctgov-nct07662213-2026-10-22`, retrieved 2026-10-26)
- Completion: 2028-05-23 (anticipated) (ClinicalTrials.gov record NCT07662213, source copy `cardio:ctgov-nct07662213-2026-10-22`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; China; Germany; Hungary; Italy; Japan; Poland; South Korea; Taiwan; United Kingdom (ClinicalTrials.gov record NCT07662213, source copy `cardio:ctgov-nct07662213-2026-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07662213-2026-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Acronym: Eluminate-2
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Elecoglipron
- Intervention (Drug): Semaglutide
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 29cd1cb63340f6dcbe9213de779c0f932152cc5ed67b471ad876d4e320cb1a14
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
